PARKINSONS UK Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2020
NCT04167813
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Parkinsons Org UK | Parkinson´s UK | PARKINSONS UK

Active Ingredients

Drugs in Phase 2 Trials (3)

azd-0328 (1 trial)

befiradol (1 trial)

ondansetron (zofran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hallucinations (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3